Neptune Technologies & Bioresources (NEPT)
Neptune Technologies & Bioresources Return on Equity: -4.97%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NEPT Return on Equity Rankings
| Overall | 20th percentile | 3235 of 4059 |
| Sector | 46th percentile | 247 of 458 in Healthcare |
| Industry | 71st percentile | 40 of 139 in Biotechnology |
NEPT Return on Equity Range, Past 5 Years
| Minimum | -15.14% | Feb 2010 |
| Maximum | 40.90% | Feb 2011 |
| Average | 14.94% |
About Return on Equity (ROE)
Click "Learn More" below to see how YCharts calculates Return on Equity.
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities). In other words, ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
You may also be interested in these NEPT related companies
NEPT News
Trading Radar for 05/31: Ciena (CIEN), Joy Global (JOY), RealD (RLD), Splunk (SPLK), Omnivision (OVTI) Report
May 30, 5:22PM Street Insider
May 30, 5:22PM Street Insider
4 breakout: $NEPT. Not much in the four stocks on offer. No penny stocks, but nothing over $10 either.
about 4 days ago by fallondpicks
about 4 days ago by fallondpicks
Elan Corporation plc, Quest Software Among Stocks Up on High Volume Friday
May 25, 12:33PM Fox Business
May 25, 12:33PM Fox Business
$NEPT http://stks.co/3z7g Breakout Watch: NEPT
see video here: http://stks.co/3z7h
about 6 days ago by MarketScanners
about 6 days ago by MarketScanners
Equity Briefing: ROTH Capital sees NEPT stock poised for significant growth this year
May 23, 8:57AM Thomson Reuters ONE
May 23, 8:57AM Thomson Reuters ONE
Neptune Believes the Australian Patent Office Will Reconsider Its Grant of Aker's Australian Patent
May 22, 3:00AM GlobeNewswire
May 22, 3:00AM GlobeNewswire
Neptune, the Only Krill Oil Manufacturer Certified as "Friend of the Sea"
May 22, 3:00AM GlobeNewswire
May 22, 3:00AM GlobeNewswire
$NEPT 200 Day SMA Cross - Price crossed above 200 day SMA (2.9486). Confirmed by volume.
about 9 days ago by TradeIdeasQuant
about 9 days ago by TradeIdeasQuant
Equity Briefing: NFL's John Elway scheduled to pitch Neptune during CNBC and Fox Business News interviews
May 10, 4:16PM Thomson Reuters ONE
May 10, 4:16PM Thomson Reuters ONE
RT @HowardGroup - NFL Legend & $NEPT Ambassador John Elway Heading to New York Natural Health Products Conference http://stks.co/3iD6
about 23 days ago by epime7heus
about 23 days ago by epime7heus
NKO(R) Ambassador John Elway to Speak at SupplySide MarketPlace (NYC) and to Visit Neptune's Booth
May 03, 8:00AM GlobeNewswire
May 03, 8:00AM GlobeNewswire
RT @dondet $NEPT my most worrisome prob w/this stock is that BioMedReports is pumping it like crazy--> noticed that too!
about 34 days ago by abubnic
about 34 days ago by abubnic
Rodman & Renshaw Starts Neptune Technologies (NEPT) at Market Outperform
Apr 26, 9:37AM Street Insider
Apr 26, 9:37AM Street Insider
Equity Briefing: Exec hints at doubling revenues and a possible spin-off dividend for NEPT investors
Apr 25, 2:48PM Thomson Reuters ONE
Apr 25, 2:48PM Thomson Reuters ONE
Co-Founder of Biotech Powerhouse, ImClone Systems, Sees the Same Type of Potential at Neptune Subsidiary
Apr 02, 7:01AM Marketwire
Apr 02, 7:01AM Marketwire
Neptune Signs John Elway, NFL Hall-of-Famer, as Official Brand Ambassador
Mar 27, 8:00AM GlobeNewswire
Mar 27, 8:00AM GlobeNewswire
RT @mikeadd $AMRN - $NEPT/Omthera..most of these trials were done in India, Russia...need I say anymore.....flushthatturd!
about 67 days ago by nobody99
about 67 days ago by nobody99
Neptune Technologies & Bioressources Investing Over $20M in Sherbrooke
Mar 09, 10:00AM GlobeNewswire
Mar 09, 10:00AM GlobeNewswire
Acasti to Present at The Annual Roth Conference and Grants Incentive Stock Options
Mar 06, 8:00AM GlobeNewswire
Mar 06, 8:00AM GlobeNewswire
Acasti Pharma's (TSXV:APO) Dr. Harlan Waksal Interviewed by Grant Howard of Howard Group - Video Hosted on www.InvestmentPitch.com
Mar 02, 2:27PM Thomson Reuters ONE
Mar 02, 2:27PM Thomson Reuters ONE
Neptune Premium Krill Oil, NKO(R) Enters the Mass Market With Jamieson Laboratories, the Largest Brand in Canada
Feb 15, 8:00AM GlobeNewswire
Feb 15, 8:00AM GlobeNewswire
Acasti Pharma Announces a Private Placement Financing of Approximately $2,000,000 CDN
Feb 07, 11:52AM GlobeNewswire
Feb 07, 11:52AM GlobeNewswire
Neptune, Aker and Schiff Agree to Stay of Litigation During Patent Re-Examination Proceedings
Feb 02, 12:24PM GlobeNewswire
Feb 02, 12:24PM GlobeNewswire
$NEPT http://stks.co/1jcl Kumo break-out on volume, closed just above the cloud, 200 day overhead
about 150 days ago by Tr8r_x
about 150 days ago by Tr8r_x
$NEPT - Neptune’s Q3/F12 Guidance Calls For Record Revenue - $5-5.25 million http://stks.co/1LSV #krill #investing
about 181 days ago by HowardGroup
about 181 days ago by HowardGroup
$NEPT - Neptune Makes the Move to the TSX – Canada’s Senior Exchange http://stks.co/1GLz
about 188 days ago by HowardGroup
about 188 days ago by HowardGroup
$NEPT - Neptune – Dr. Oz says Krill Omega 3 is Superior to Fish Oil http://stks.co/1Fnj #DrOz
about 189 days ago by HowardGroup
about 189 days ago by HowardGroup
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NEPT | 3.80 | +0.00 | +0.00% | 183.46M |
| NEP | 3.11 | +0.00 | +0.00% | 110.28M |
| NEOG | 38.47 | -0.09 | -0.23% | 907.32M |
| NEN | 27.00 | +0.00 | +0.00% | 85.32M |
| NEM | 47.85 | -0.33 | -0.68% | 23.62B |
| NEI | 0.80 | +0.01 | +1.27% | 33.61M |
| NEE | 65.15 | -0.49 | -0.75% | 27.32B |
| NEBS | 9.78 | -0.71 | -6.77% | 63.99M |
| NEA | 15.00 | -0.02 | -0.13% | |
| NE | 32.61 | -1.54 | -4.51% | 8.612B |
